Kangpu Biopharmaceuticals, Ltd. is a China-based biopharmaceutical startup founded in 2011. The company focuses on developing innovative small molecules for treating solid tumors, hematological malignancies, auto-immune diseases, and inflammatory disorders. It specializes in targeted protein ubiquitination and degradation, offering novel-generation solutions. Kangpu has a strong management team and a robust pipeline of potential first-in-class and best-in-class drug candidates. One of its notable developments is X-Synergy®, a proprietary drug combination technology for treating metastatic and non-metastatic castration-resistant prostate cancer.
Notably, Kangpu recently received a substantial CNY100.00M Series B investment on 30 August 2023. The investment was led by Northern Light Venture Capital, Yijing Capital, 浙江银杏谷投资有限公司, Ruihe Capital, Longpan Investment, Yicun Capital, and Xiaochi Capital.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | CNY100.00M | 7 |
|
30 Aug 2023 |
| Series B | CNY250.00M | 3 |
|
10 May 2021 |
| Series A | $14.00M | - | 09 Aug 2019 |
No recent news or press coverage available for Kangpu Biopharmaceuticals, Ltd..
We care about your data, and we'd love to use cookies make your experience better.
